BioCryst Pharmaceuticals (BCRX) said Monday a study of berotralstat, which it markets under the brand name of Orladeyo, showed a significant reduction in hospitalizations, emergency room visits, and use of on-demand therapies for patients with hereditary angioedema in the US.
The company said that the study of berotralstat will be presented at the Academy of Managed Care Pharmacy Nexus 2024 national meeting being held in Las Vegas, Nevada, this week.
Price: 7.59, Change: +0.16, Percent Change: +2.15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments